Inebilizumab Clinical Trials (2026): 18 Studies for Neuromyelitis Optica Spectrum Disorder & Neuromyelitis Optica Spectrum Disorders
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Inebilizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Neuromyelitis Optica Spectrum Disorder & Neuromyelitis Optica Spectrum Disorders) and 2,175 total planned enrollment. 5 Phase 3 Inebilizumab trials and 6 Phase 2, 3 Phase 4 are listed. 9 Inebilizumab clinical trials are actively recruiting at 54 U.S. sites across 23 states. Most recent activity: NCT07598825 (Feb 2034).
Where to Participate: All Inebilizumab Trial Sites in the U.S. (54 sites across 23 states)
Every actively recruiting Inebilizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama at Birmingham | Birmingham35233 | NCT04372615 | Map |
| AZ | St. Joseph Hospital and Medical Center Barrow Neurological Institute | Phoenix85013 | NCT04372615 | Map |
| AZ | HonorHealth Research and Innovation Institute | Scottsdale85258 | NCT06570798 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT04372615 | Map |
| CA | UCSD Altman Clinical and Translational Research Institute Building | La Jolla92037-1337 | NCT05549258 | Map |
| CA | Loma Linda University Children's Hospital - PIN | Loma Linda92354 | NCT05549258 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT04372615 | Map |
| CA | UC Irvine | Orange92868 | NCT04372615 | Map |
| CA | UC Davis | Sacramento95816 | NCT04372615 | Map |
| CO | Children's Hospital Colorado Main Campus | Aurora80045 | NCT04372615 | Map |
| CO | University of Colorado | Aurora80045 | NCT04372615 | Map |
| CO | University of Colorado | Aurora80045 | NCT06570798 | Map |
| CT | Yale University | New Haven06510 | NCT04372615 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224 | NCT04372615 | Map |
| FL | University of Miami | Miami33136 | NCT04372615 | Map |
| FL | Bioresearch Partner Coral Terrace | South Miami33143 | NCT06570798 | Map |
| GA | Emory University | Atlanta30322 | NCT04372615 | Map |
| IL | Ann and Robert H. Lurie Childrens Hospital of Chicago | Chicago60611 | NCT04372615 | Map |
| IL | Northwestern University Feinberg School of Medicine | Chicago60611 | NCT04372615 | Map |
| IA | University of Iowa | Iowa City52242 | NCT04372615 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT06570798 | Map |
| MA | Massachusetts General Hospital | Boston02115 | NCT05549258 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04372615 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06570798 | Map |
| MI | University of Michigan Health System | Ann Arbor48109 | NCT04372615 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06570798 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT04372615 | Map |
| MO | Washington University in St. Louis School of Medicine | St Louis63110 | NCT04372615 | Map |
| NY | SUNY Downstate | Brooklyn11203 | NCT04372615 | Map |
| NY | Northwell Health | Great Neck11021 | NCT06570798 | Map |
| NY | Westchester Medical Center | Hawthorne10532 | NCT06570798 | Map |
| NY | Columbia University Medical Center | New York10033 | NCT04372615 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT06570798 | Map |
| NY | Mount Sinai | New York10029 | NCT04372615 | Map |
| NY | University of Rochester | Rochester14618 | NCT04372615 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT06570798 | Map |
| NY | SUNY Buffalo | Williamsville14221 | NCT04372615 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27101 | NCT04372615 | Map |
| OH | University of Cincinnati | Cincinnati45219 | NCT04372615 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06570798 | Map |
| OH | MetroHealth Medical Center | Cleveland44109 | NCT06570798 | Map |
| OH | Ohio State University | Columbus43210 | NCT04372615 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT04372615 | Map |
| PA | University of Pittsburgh | Pittsburgh15213 | NCT04372615 | Map |
| TN | Vanderbilt University | Nashville37212 | NCT04372615 | Map |
| TX | Austin Neuromuscular Center | Austin78759 | NCT06987539 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas78701 | NCT05549258 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT04372615 | Map |
| TX | Prolato Clinical Research Center | Houston77054 | NCT06570798 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT04372615 | Map |
| UT | University of Utah | Salt Lake City84108 | NCT04372615 | Map |
| VA | University of Virginia | Charlottesville22903 | NCT04372615 | Map |
| WA | Seattle Rheumatology Associates | Seattle98104 | NCT06570798 | Map |
| WA | University of Washington | Seattle98195 | NCT04372615 | Map |
Inebilizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|
| P2 | 4 | 1 | 1 | 6 | |||
| P2/P3 | 1 | 1 | |||||
| P3 | 3 | 2 | 5 | ||||
| P4 | 1 | 1 | 1 | 3 | |||
| N/A | 1 | 2 | 3 |
Recruiting Inebilizumab clinical trials (9)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07598825 | MERCURYA Trial of Inebilizumab in Participants With Autoimmune Hepatitis | P3 | Autoimmune Hepatitis | 180 | Sep 2026 |
| NCT07222553 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD | P2 | Immunoglobulin G4-related Disease | 15 | Jul 2026 |
| NCT07010302 | BEST-NMOSDRituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | P4 | NMOSD | 540 | Aug 2026 |
| NCT06987539 | THYMEA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | P2 | Generalized Myasthenia Gravis | 15 | Aug 2026 |
| NCT04372615 | ExTINGUISHThe ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis | P2 | Autoimmune Encephalitis | 116 | Mar 2022 |
| NCT07132398 | STARGlu-NMOSlow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD | P3 | Neuromyelitis Optica (NMO) | 170 | Sep 2025 |
| NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | P2 | Systemic Lupus Erythematosus | 220 | Jul 2025 |
| NCT05549258 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | P2 | Neuromyelitis Optica Spectrum Disorder | 15 | Jul 2023 |
| NCT07159893 | Inectolizumab With Steroid Optimization in Newly Treated NMOSD | N/A | Neuromyelitis Optica | 25 | Sep 2025 |
Inebilizumab clinical trials by indication
Neuromyelitis Optica Spectrum Disorder (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06180278 | N-MOmentum LT | P4 | active not recruiting | Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) |
| NCT05549258 | — | P2 | recruiting | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder |
| NCT05891379 | — | N/A | unknown | Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders |
Neuromyelitis Optica Spectrum Disorders (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06068829 | — | N/A | unknown | Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders |
| NCT06212245 | — | P4 | unknown | A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders |
Autoimmune Hepatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07598825 | MERCURY | P3 | not yet recruiting | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis |
Generalized Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06987539 | THYME | P2 | recruiting | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) |
Immunoglobulin G4-related Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07222553 | — | P2 | not yet recruiting | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD |
NMOSD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07010302 | BEST-NMOSD | P4 | not yet recruiting | Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD |
Neuromyelitis Optica (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07159893 | — | N/A | not yet recruiting | Inectolizumab With Steroid Optimization in Newly Treated NMOSD |
Neuromyelitis Optica (NMO) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07132398 | STARGlu-NMO | P3 | not yet recruiting | Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06570798 | — | P2 | recruiting | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases |
Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05198557 | — | P3 | active not recruiting | A Study of MT-0551 in Patients With Systemic Sclerosis |
Autoimmune Encephalitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04372615 | ExTINGUISH | P2 | recruiting | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis |
IgG4 Related Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04540497 | — | P3 | active not recruiting | A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease |
Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04524273 | MINT | P3 | active not recruiting | Myasthenia Gravis Inebilizumab Trial |
Highly Sensitized Patients on Waiting List for Kidney Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04174677 | — | P2 | withdrawn | Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor |
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02200770 | — | P2/P3 | completed | N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders |
Inebilizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BEST-NMOSD | NCT07010302 | P4 | not yet recruiting | NMOSD | 540 | PMID 36007339 |
| N-MOmentum LT | NCT06180278 | P4 | active not recruiting | Neuromyelitis Optica Spectrum Disorder | 32 | — |
| MERCURY | NCT07598825 | P3 | not yet recruiting | Autoimmune Hepatitis | 180 | — |
| MINT | NCT04524273 | P3 | active not recruiting | Myasthenia Gravis | 238 | PMID 40202593 |
| STARGlu-NMO | NCT07132398 | P3 | not yet recruiting | Neuromyelitis Optica (NMO) | 170 | — |
| THYME | NCT06987539 | P2 | recruiting | Generalized Myasthenia Gravis | 15 | — |
| ExTINGUISH | NCT04372615 | P2 | recruiting | Autoimmune Encephalitis | 116 | PMID 29476014 |
Terminated and withdrawn Inebilizumab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04174677withdrawnSafety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
All Inebilizumab trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07598825 | MERCURY | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | P3 | not yet recruiting | 180 | Amgen | Sep 2026 |
| NCT07222553 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD | P2 | not yet recruiting | 15 | Amgen | Jul 2026 | |
| NCT07010302 | BEST-NMOSD | Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | P4 | not yet recruiting | 540 | Massachusetts General Hospital | Aug 2026 |
| NCT06987539 | THYME | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | P2 | recruiting | 15 | Amgen | Aug 2026 |
| NCT04524273 | MINT | Myasthenia Gravis Inebilizumab Trial | P3 | active not recruiting | 238 | Amgen | Oct 2020 |
| NCT04540497 | A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease | P3 | active not recruiting | 135 | Amgen | Dec 2020 | |
| NCT04372615 | ExTINGUISH | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis | P2 | recruiting | 116 | University of Utah | Mar 2022 |
| NCT07132398 | STARGlu-NMO | Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD | P3 | not yet recruiting | 170 | Tianjin Medical University General Hospital | Sep 2025 |
| NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | P2 | recruiting | 220 | Amgen | Jul 2025 | |
| NCT06180278 | N-MOmentum LT | Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) | P4 | active not recruiting | 32 | Amgen | Apr 2024 |
| NCT05549258 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | P2 | recruiting | 15 | Amgen | Jul 2023 | |
| NCT07159893 | Inectolizumab With Steroid Optimization in Newly Treated NMOSD | N/A | not yet recruiting | 25 | First Affiliated Hospital of Wenzhou Medical University | Sep 2025 | |
| NCT05198557 | A Study of MT-0551 in Patients With Systemic Sclerosis | P3 | active not recruiting | 80 | Tanabe Pharma Corporation | Jul 2022 | |
| NCT05891379 | Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders | — | unknown | 50 | Xuanwu Hospital, Beijing | Jul 2024 | |
| NCT06068829 | Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders | — | unknown | 80 | Feng Jinzhou | Oct 2023 | |
| NCT06212245 | A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders | P4 | unknown | 33 | Hansoh BioMedical R&D Company | Feb 2024 | |
| NCT04174677 | Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor | P2 | withdrawn | 0 | Amgen | Dec 2019 | |
| NCT02200770 | N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders | P2/P3 | completed | 231 | MedImmune LLC | Apr 2015 |
Inebilizumab clinical trials: frequently asked questions
- How many Inebilizumab clinical trials are there?
- 18 Inebilizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 1 is marked completed.
- Are Inebilizumab clinical trials recruiting in 2026?
- Yes — 4 Inebilizumab trials are actively recruiting in 2026, with 54 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Inebilizumab being studied for?
- Inebilizumab is being studied for Neuromyelitis Optica Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Autoimmune Diseases, Autoimmune Encephalitis, Autoimmune Hepatitis and 16 more. The trials are grouped by indication on this page.
- What phase is Inebilizumab in?
- Inebilizumab clinical trials span 3 Phase 4, 5 Phase 3, 6 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Inebilizumab clinical trials?
- The lead sponsor across the most Inebilizumab trials is Amgen, with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Inebilizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: